Search clinical trials for: JNJ-42160443 (1 mg)

Total 1362 results

Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Diabetic Neuropathy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

Low Back Pain | Low Back Pain, Recurrent

United States, Belgium, Canada, Netherlands
Janssen Research & Development, LLC

Completed

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Pain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, Splitting

United States, France, Spain, Poland, Portugal
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Pain | Mononeuropathies | Neuralgia | Neuralgia, Postherpetic

United States, Spain, Belgium, Netherlands
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

Urologic Diseases | Urinary Bladder Diseases | Cystitis | Cystitis, Interstitial

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

Pain | Osteoarthritis | Joint Pain | Arthralgia | Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, Canada, Korea, Republic of
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

Healthy

Belgium
Janssen Pharmaceutical K.K.

Completed

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

Healthy

United States
Janssen Research & Development, LLC

Terminated

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

Alzheimer Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

Healthy

United States
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Janssen Research & Development, LLC

Terminated

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Solid Formulations of JNJ-39393406 in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

Alzheimer's Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Johnson & Johnson Pharmaceutical Research & Development...

Withdrawn

Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma

Asthma
Janssen Pharmaceutical K.K.

Completed

Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia

Alzheimer's Disease

Japan
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Germany, Netherlands
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

Influenza A Virus

Belgium
Janssen Pharmaceutical K.K.

Terminated

A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis

Dermatitis, Atopic

Japan
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease

Alzheimer Disease

Spain, Netherlands, Belgium, Sweden
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

Atopic Dermatitis

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants

Healthy

Japan, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

United States, Poland
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

Healthy

Belgium
Janssen R&D Ireland

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients

Chronic Hepatitis C Infection

Taiwan
Janssen Research & Development, LLC

Withdrawn

A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate

Active Rheumatoid Arthritis; Rheumatoid Arthritis
Janssen-Cilag International NV

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery (TEXT-TKR)

VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Belgium, Italy, Malaysia, Latvia, Spain, Turkey, Bulgaria, United States, Lithuania, Russian Federation, Ukraine, Japan, Argentina, Brazil, Canada, Poland
Janssen Sciences Ireland UC

Terminated

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (FREESIA)

Respiratory Syncytial Virus Infections

United States, Belgium, Taiwan, Israel, Japan, Argentina, Malaysia, Korea, Republic of, Netherlands, Spain, Australia, Italy, Brazil, France, United Kingdom, Sweden, Bulgaria
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery (AXIOMATIC-TKR)

Arthroplasty, Replacement, Knee

Israel, Belgium, Italy, United States, Spain, Hungary, Portugal, Russian Federation, Japan, Turkey, Ukraine, Greece, Poland, Argentina, Brazil, Bulgaria, Canada, South Africa
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Respiratory Syncytial Viruses

Taiwan, Belgium, United Kingdom, Argentina, Panama
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

Sleep Apnea, Obstructive

United States
Janssen Research & Development, LLC

Completed

A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants

Healthy

Netherlands
Janssen-Cilag International NV

Completed

A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants

Healthy Volunteers | Pharmacokinetics

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus

Obesity and Diabetes Mellitus, Type 2

United States
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris

Acne Vulgaris

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-61393215 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Research & Development, LLC

Terminated

A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) (DAISY)

Respiratory Tract Infections

Belgium, Czechia, Taiwan, Japan, Hungary, Thailand, United States, Germany, Korea, Republic of, Turkey, China, Spain, Brazil, Bulgaria, Malaysia, Estonia, Argentina, Poland, Israel, Italy, Latvia, Mexico, Panama, Slovakia, Sweden, Ukraine
Aragon Pharmaceuticals, Inc.

Completed

Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma

Tumor or Lymphoma

United States, France, Spain
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

Healthy

Belgium

3

Subscribe